Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 15/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 15/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13793469 | 0.92 | MCHR1 (0.61) | ADRA2AMCHR1NPY5RAKR1C2HTR1A | |
| SCHEMBL13795435 | 0.87 | ADRA2A (0.53) | ADRA2AMCHR1NPY5RHTR1AADRA1A | |
| SCHEMBL13793428 | 0.84 | MCHR1 (0.59) | ADRA2AMCHR1NPY5RHTR1AADRA1A | |
| SCHEMBL13794780 | 0.84 | MCHR1 (0.58) | ADRA2AMCHR1NPY5RHTR1AADRA1A | |
| SCHEMBL13793296 | 0.83 | MCHR1 (0.57) | ADRA2AMCHR1NPY5RHTR1AADRA1A | |
| SCHEMBL13797071 | 0.83 | MCHR1 (0.59) | ADRA2AMCHR1NPY5RHTR1AADRA1A | |
| SCHEMBL13793938 | 0.83 | MCHR1 (0.66) | ADRA2AMCHR1NPY5RHTR1AADRA1A | |
| SCHEMBL6878054 | 0.83 | EIF2AK2 (0.49) | MCHR1AKR1C2HDAC1MTNR1AMTNR1B | |
| SCHEMBL6878048 | 0.83 | EIF2AK2 (0.49) | MCHR1AKR1C2HDAC1MTNR1AMTNR1B | |
| SCHEMBL13795784 | 0.83 | MCHR1 (0.54) | ADRA2AMCHR1NPY5RHTR1AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544690-B2 | MCH receptor antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544690-B2 | MCH receptor antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | MCHR1, MCHR2, MC4R | ADRA2A 131/4885MCHR1 1/4885NPY5R 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.